HIV Pregnancy Hotline Homepage
Medical Information Linking Patients to Care Rapid HIV Testing
About The Hotline
> About the Hotline > Hotline FAQ > Hotline Release of Information Forms > Support Us
HIV Treatment Guidelines & Medical Information
> HIV Treatment Guidelines & Medical Information > Treatment Guidelines > Pregnancy and HIV FAQ > Neonatology/Pediatrics and HIV FAQ > Recent Articles
Rapid HIV Testing
> Rapid HIV Testing > Rapid HIV Testing FAQ > Forms for Reporting a Preliminary Positive Rapid HIV Test > Forms for Monthly Perinatal HIV Reporting  > Rapid HIV Testing Implementation Resources > Expedited Western Blot Test Information
Enhanced Case Management
> Enhanced Case Management > Enhanced Case Management FAQ > Enhanced Case Management Consent Forms > Case Management Protocols > Real Life Patient Stories
Resource Center & Forms
> Resource Center & Forms > All Forms > Updates > Helpful Links > Other HIV Hotlines
Information for Providers
> Information for Providers > Obstetric Health Care Providers > Pediatric Health Care Providers > Social Service Providers
Pregnant & Positive
> Pregnant & Positive > Pregnancy and HIV FAQ > Support Groups > HIV Prenatal Classes
Illinois Perinatal HIV Prevention Act
> Illinois Perinatal HIV Prevention Act > IL Perinatal HIV Prevention Act FAQ > Reporting Requirements
Our Partners
> Our Partners > Pediatric AIDS Chicago Prevention Initiative > Perinatal Rapid Testing Implementation Initiative in Illinois > Illinois Department of Public Health > AIDS Foundation of Chicago > Sources of HIV related Obstetric and Pediatric Care
Contact Us Get Involved  
 Follow Us

For non-pregnancy related questions about HIV, please call 1-800-AID-AIDS

Update

NIH Discontinues Tenofovir Vaginal Gel in VOICE Study - 12/2/2011

In a press release last week, the NIH announced it was discontinuing the Tenofovir vaginal gel arm of the VOICE HIV Prevention Study as it has not been shown to be effective in reducing HIV transmission over a placebo gel.  This comes two months after the announcement of the discontinuing of the oral tenofovir arm of the study due to inability to demonstrate effectiveness.

Press Release - Tenofovir Gel

Press Release - Oral Tenofovir